Navigation Links
TGen partner, PBS-Bio, makes first breakthrough drug analysis

PHOENIX, Ariz. June 18, 2010 Predictive Biomarker Sciences Inc. (PBS-Bio) has completed its first drug analysis, enabling Canadian biotech company PharmaGap Inc. to significantly advance a potentially significant anti-cancer medication.

PharmaGap is an early-stage biotech company based in Ottawa, Ontario developing novel peptide compounds for cancer. Its lead compound, GAP-107B8, exhibits potent cytotoxic characteristics against cancer cells and has recently completed screening at the National Cancer Institute in Bethesda, Md., and was the subject of a data poster by researchers at the Ottawa Hospital Research Institute at the recent American Association for Cancer Research meeting in Washington, D.C.

Proprietary real-time computer imaging technology from PBS-Bio has been instrumental in assisting PharmaGap to determine the drug's potential mechanism of action and thereby identifying suitable cancers to target for eventual clinical use.

As part of its pre-clinical development program, PharmaGap hired Phoenix-based PBS-Bio to analyze more specifically how the drug worked. PBS-Bio is a privately held, for-profit corporation owned in part by the non-profit Translational Genomics Research Institute (TGen).

Data from the PBS-Bio analysis indicated that GAP-107B8 rapidly compromises the outer membrane of colorectal cancer cells, leading to either oncolytic or apoptotic cell death, while having significantly less affect on non-cancerous cells.

Unlike many protein kinase inhibitor drugs now in development, GAP-107B8 works within mere minutes through "an assault on the plasma membrane," said Dr. Isabella Steffensen, a PharmaGap pre-clinical development consultant. She said that GAP-107B8 appears to be reacting with surface receptors apparently more prevalent on cancer cells than normal cells.

By providing PharmaGap with a more accurate analysis of how the drug functioned, PBS-Bio saved the company months of research and an estimated $400,000 in costs.

Moreover, the PBS-Bio data has assisted PharmaGap to expand the scope of possible cancer targets for GAP-107B8, said Robert McInnis, the company's President and Chief Executive Officer.

McInnis said PharmaGap is now also better positioned with GAP-107B8 to run clinical trials, anticipated in 2012, and expand the scope of its intellectual property and business development potential.

"Based on the insights gleaned from working with the PBS-Bio team in Arizona, we have a much clearer idea of how this compound is acting," McInnis said. "Overall, it was a very successful collaboration. We certainly look forward to a continuing relationship with PBS-Bio"

Like plugging a computer diagnostic into a running car engine, PBS-Bio's technology uses live cancer cells to show pharmaceutical companies how their drugs work, or don't work, said Dr. Michael Bittner, Co-Director of TGen's Computational Biology Division.

"For the first time, we can show at the molecular level exactly how drugs will affect cancer cells in real-time, identifying precisely along which cellular pathways drugs produce results, or fail,'' said Dr. Bittner, who also is a Principal Investigator at TGen for the PBS-Bio technology, and a Member of PBS-Bio's Scientific Advisory Board.

"The success of targeted oncology drugs can vary from tumor to tumor, and the range of the specific types of tumor molecular pathologies that are susceptible or resistant to a given drug are frequently unknown. The purpose of the PBS-Bio technology is to make pre-clinical research more predictive of actual patient outcomes," Dr. Bittner said.

The technology is expected to save pharmaceutical companies millions of dollars in drug development costs, especially by showing what drugs might not work, thereby avoiding costly clinical trials, said Dr. Edward Smith, founder and CEO of PBS-Bio.

The technology also is expected to show which drugs might work better in tandem with other drugs, thereby salvaging promising drug lines that otherwise might be shelved, said Dr. Smith, who also is an adjunct faculty member at TGen and at the University of Arizona College of Medicine.

"Specifically, the TGen-PBS-Bio technology shows, in real time, how drugs affect the genes and their signaling pathways within cells that cause cancers to grow out of control," Dr. Smith said.

The hope is that by using this technology, drug companies will be able to develop cancer drugs more quickly, and at lower costs, while giving researchers a better idea of which patients will best respond to the therapies, Dr. Smith said.

PBS-Bio is working with three large pharmaceutical companies on projects to: determine which of several similar compounds to move into clinical trials, identify which drugs to add to their investigational drug to make it most effective, and identify biomarker tests that will identify patients most likely to respond to the new drug combination.


Contact: Steve Yozwiak
The Translational Genomics Research Institute

Related medicine news :

1. After a fight with a partner, brain activity predicts emotional resiliency
2. Life Line Screening Proudly Supports NBC's Skate for the Heart in Honor of Longtime Partner, Peggy Fleming
3. Revolutionary scale makes losing weight easier than ever
4. "How Facebook Makes Lonely People Even Lonelier" Revealed by Distinguished University of Chicago Professor in Interview with Brian Vaszily on
5. Spending time in nature makes people feel more alive, study shows
6. ACR task force makes recommendations for improving relationships between radiologists and hospitals
7. ORCS Web, Inc Makes Available WCF RIA Services
8. Surpasses 100,000 Meal Milestone; Web Site Makes Caring For Friends and Family Easier
9. Fight Obesity with Fitness Entrepreneur's New Product That Makes Inline Skating Safer
10. Safety Training Makes for Safer Mining
11. Wine Enthusiast Facebook Sweepstakes Makes One in Twenty a Winner
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... It takes only ... a business, it is critical that the first impression be positive and reflects business ... not likely to buy anything or want to return. They will also share their ...
(Date:11/24/2015)... ... 24, 2015 , ... United Benefit Advisors (UBA), the nation’s ... as its newest Partner Firm. Based in Jefferson City, Missouri, their core philosophy ... regardless of whether that client is a business, a family, or an individual. ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Serenity Point Rehabilitation, ... series of recent video interviews with some of the staff members at their recovery ... residential treatment facility, as well as some of the things that make their recovery ...
(Date:11/24/2015)... ... 2015 , ... Abington Hospital – Jefferson Health is pleased ... Surgery Facility for treating individuals living with morbid or extreme obesity. , Aetna ... its members to help them make informed decisions about their healthcare needs. In ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty ... Program have announced their endorsement of the Medical Fitness Network (MFN), a ... proud to have the MFN as one of our endorsed organizations,” said ASH ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015 iRhythm Technologies, Inc. , a ... today announced that it will participate in the 27th Annual Piper ... New York, NY . Kevin King , ... December 1, 2015 at 8:50am ET. --> ... . --> . --> iRhythm ...
(Date:11/24/2015)... Ontario , Nov. 24, 2015 Teledyne ... digital X-Ray image sensing technology, will introduce its CMOS ... Technical Exhibition , November 29 to December 3, at McCormick ... of dynamic detectors for diagnostic and interventional imaging will be ... Xineos family of advanced CMOS X-Ray detectors is ...
(Date:11/24/2015)... The uptake of recently approved and pipeline premium products for ... growth to 2021, says GBI Research . ... Type 1 Diabetes Mellitus (T1DM), will be a key driver of market ... --> The uptake of recently approved and pipeline premium products ... market growth to 2021, says GBI Research . ...
Breaking Medicine Technology: